AUTHOR=Wang Cong , Chen Fang , Liu Yichen , Xu Qingqing , Guo Liang , Zhang Xiaoqing , Ruan Yunfeng , Shi Ye , Shen Lu , Li Mo , Du Huihui , Sun Xiaofang , Ma Jingsong , He Lin , Qin Shengying TITLE=Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients JOURNAL=Frontiers in Pharmacology VOLUME=9 YEAR=2018 URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00360 DOI=10.3389/fphar.2018.00360 ISSN=1663-9812 ABSTRACT=
The efficacy of erlotinib treatment for advanced non-small cell lung cancer (NSCLC) is due to its action as an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Patients treated with erlotinib experience different drug responses. The effect of germline mutations on therapeutic responses and adverse drug responses (ADRs) to erlotinib in Chinese patients requires elucidation. Sixty Han Chinese advanced non-small cell lung cancer patients received erlotinib monotherapy and, for each participant, 76 candidate genes (related to EGFR signaling, drug metabolism and drug transport pathways) were sequenced and analyzed. The single-nucleotide polymorphisms (SNPs) rs1042640 in